Work

The Landscape of Vascular Endothelial Growth Factor Inhibition in Retinal Diseases

Year: 2025

Type: article

Abstract: Ever since the US Food and Drug Administration (FDA) approved the first vascular endothelial growth factor (VEGF) antagonist 2 decades ago, inhibitors of VEGF have revolutionized the treatment of a variety of ocular disorders involving pathologic neovascularization and retinal exudation. In this perspective, we evaluate the current status of anti-VEGF therapies and the real-world challenges encountered with maintaining therapeutic outcomes. Finally, we describe novel VEGF-based and combinatorial approaches that are in clinical development.

Source: Investigative Ophthalmology & Visual Science

DOI: 10.1167/iovs.66.1.47

Authors: Joseph B. Lin, Rajendra S. Apte

Institution: Washington University in St. Louis

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,850